European Commission strikes deal with manufacturer for 300 million doses of promising coronavirus vaccine
Thanks to an agreement with the French pharmaceutical group Sanofi, the European Commission will provide the EU countries with 300 million doses of the developed COVID-19 vaccine. Each member state will be able to purchase the vaccine if clinical trials demonstrate the efficacy and safety of the vaccine, the commission said.
“The forthcoming agreement with Sanofi will allow all member states to purchase the vaccine,” the EC said.
“We have advanced in the debates with several other companies. Because we do not know which vaccine will work best in the end, Europe is investing in a diverse portfolio of promising substances from different technologies. This increases our chances of getting a virus fight quickly,” said Ursula von der Leyen, head of the commission.
There are currently more than 150 possible COVID-19 vaccines at various stages of development. For example, in which researchers from Oxford University are collaborating, the AstraZeneca vaccine is in an advanced stage of testing. The AZD1222 vaccine, according to a study by The Lancet, has no side effects.
Pfizer is developing its vaccine in collaboration with the German biotechnology company BioNTech and still has an extensive third phase of clinical trials ahead of it. According to recently published results in the first round of testing, one of its experimental vaccines elicited some patients’ desired immune response.
The Czech Minister of Health, Adam Vojtech, stated this week that, according to current calculations, the Czechia would need about 3.5 million doses of the COVID-19 vaccine.